HKSE - Delayed Quote HKD

SIHUAN PHARM (0460.HK)

0.670

+0.010

+(1.52%)

At close: 4:08:18 PM GMT+8

Xuanzhu Biopharm's Xuanyuening® (BireociclibTablets) Approved for Dual Indications, Bringing Innovative Breakthroughs to Breast Cancer Treatment

On May 15, 2025, the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade name: Xuanyuening®), a Class 1 anti-tumor new drug independently developed by Xuanzhu Biopharmaceutical was officially approved for marketing. This innovative drug is indicated for two important conditions in HR+/HER2- breast cancer. It not only injects new vitality into the domestic br

PR Newswire 9 hours ago

SHPHF
Asian Market Insights: Sihuan Pharmaceutical Holdings Group And 2 Other Promising Penny Stocks

As trade tensions between the U.S. and China show signs of easing, Asian markets are experiencing a cautious optimism, with indices like China's CSI 300 and Japan's Nikkei 225 making gains. In this context, penny stocks—though often seen as relics of past trading days—remain relevant for investors seeking opportunities in smaller or newer companies that may offer surprising value. This article will explore three such penny stocks in Asia, including Sihuan Pharmaceutical Holdings Group, which...

Simply Wall St. 15 days ago

SHPHF
Asian Market Opportunities: SSY Group And 2 Promising Penny Stocks

Amidst global economic uncertainty and inflation fears, Asian markets are navigating a complex landscape shaped by trade policy shifts and consumer sentiment challenges. In this context, penny stocks—often representing smaller or newer companies—remain an intriguing area for investors seeking unique growth opportunities. While the term "penny stocks" might seem outdated, these investments can still offer potential when backed by strong financials, as we explore with SSY Group and two other...

Simply Wall St. last month

0838.HK

SHPHF

LJUIF

Performance Overview

Return	0460.HK	HANG SENG INDEX (^HSI)
YTD	+1.52%	+16.38%
1-Year	+12.20%	+20.48%
3-Year	-25.74%	+17.02%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SIHUAN PHARM (0460.HK)

Xuanzhu Biopharm's Xuanyuening® (BireociclibTablets) Approved for Dual Indications, Bringing Innovative Breakthroughs to Breast Cancer Treatment

Asian Market Insights: Sihuan Pharmaceutical Holdings Group And 2 Other Promising Penny Stocks

Asian Market Opportunities: SSY Group And 2 Promising Penny Stocks

Performance Overview